dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Gallardo, Eduard |
dc.contributor.author | Medina, Javier |
dc.contributor.author | Sanchez, Juan Cristobal |
dc.contributor.author | Viudez, Antonio |
dc.contributor.author | Porras, Ignacio |
dc.contributor.author | Capdevila Castillon, Jaume |
dc.contributor.author | Grande, Enrique |
dc.date.accessioned | 2021-09-15T07:39:30Z |
dc.date.available | 2021-09-15T07:39:30Z |
dc.date.issued | 2020-02 |
dc.identifier.citation | Gallardo E, Medina J, Sánchez JC, Viúdez A, Grande E, Porras I, et al. SEOM clinical guideline thyroid cancer (2019). Clin Transl Oncol. 2020 Feb;22:223–235. |
dc.identifier.issn | 1699-3055 |
dc.identifier.uri | https://hdl.handle.net/11351/6314 |
dc.description | Multidisciplinary; Systemic therapy; Thyroid cancer |
dc.description.abstract | Thyroid carcinoma is the most frequent endocrine malignancy and accounts for around 3% of global cancer incidence. Different histologies and clinical scenarios make necessary a multidisciplinary approach that includes new diagnostic methods and surgical, radiopharmaceutical and systemic therapies. This guideline updates several aspects of management of thyroid cancer. |
dc.language.iso | eng |
dc.publisher | Springer |
dc.relation.ispartofseries | Clinical and Translational Oncology;22 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Tiroide - Càncer - Tractament |
dc.subject | Protocols clínics |
dc.subject.mesh | Thyroid Neoplasms |
dc.subject.mesh | /therapy |
dc.subject.mesh | Practice Guidelines as Topic |
dc.title | SEOM clinical guideline thyroid cancer (2019) |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1007/s12094-019-02284-8 |
dc.subject.decs | neoplasias de la tiroides |
dc.subject.decs | /terapia |
dc.subject.decs | guías de práctica clínica como asunto |
dc.relation.publishversion | https://doi.org/10.1007/s12094-019-02284-8 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Gallardo E] Oncology Department, Parc Taulí Hospital Universitari, Institut d’Investigació i Innovació Parc Taulí I3PT, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Medina J] Oncology Department, Hospital Virgen de la Salud, Toledo, Spain. [Sánchez JC] Oncology Department, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain. [Viúdez A] Oncology Department, Complejo Hospitalario de Navarra, Pamplona, Spain. [Grande E] Oncology Department, MD Anderson Cancer Center, Madrid, Spain. [Porras I] Oncology Department, Hospital Universitario Reina Sofía, Córdoba, Spain. [Capdevila J] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain |
dc.identifier.pmid | 32006340 |
dc.identifier.wos | 000514525700007 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |